Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$59.00T
24h Vol:
$9.86B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  XENE

Xenon Pharmaceuticals Inc

XENE
46 / 100
$49.63arrow_drop_up1.01%$0.50

Performance History

Stocklytics logo
Key Stats
Open$49.21
Prev. Close$49.25
EPS-2.66
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.72B
PE Ratio-
LOWHIGH
Day Range48.74
49.51
52 Week Range27.98
50.98
Ratios
P/B Ratio5.84
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-39.62%
EBITDA Margin %-
ROE %-25.19%
EPS-2.66

Score Breakdown

46vs 53. Market Avg.

All Score 46 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

XENEMARKET
Value1339
Quality3140
Ownership019
Growth6946
Dividends-37
check_circle

Xenon Pharmaceuticals Inc's Price growth average in the last 3 years of 41.26% is great compared to market average of 6.65%. This indicates XENE could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$769.53
24H (%)arrow_drop_down-0.01%
24H ($)-$0.10
MARKET CAP$731.18B
PRICE$527.23
24H (%)arrow_drop_up0.14%
24H ($)$0.73
MARKET CAP$487.65B
PRICE$161.84
24H (%)arrow_drop_up0.86%
24H ($)$1.39
MARKET CAP$389.83B
PRICE$129.45
24H (%)arrow_drop_up0.14%
24H ($)$0.19
MARKET CAP$328.02B

About Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
Headquarters
Burnaby
Employees
203
Exchange
NASDAQ
add Xenon Pharmaceuticals Inc to watchlist

Keep an eye on Xenon Pharmaceuticals Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Xenon Pharmaceuticals Inc's (XENE) price per share?

The current price per share for Xenon Pharmaceuticals Inc (XENE) is $49.46. The stock has seen a price change of $0.21 recently, indicating a 0.43% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Xenon Pharmaceuticals Inc (XENE)?

For Xenon Pharmaceuticals Inc (XENE), the 52-week high is $50.98, which is 3.07% from the current price. The 52-week low is $27.98, the current price is 76.74% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Xenon Pharmaceuticals Inc (XENE) a growth stock?

Xenon Pharmaceuticals Inc (XENE) has shown an average price growth of 41.26% over the past three years. It has received a score of 91 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Xenon Pharmaceuticals Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Xenon Pharmaceuticals Inc (XENE) stock price performance year to date (YTD)?

As of the latest data, Xenon Pharmaceuticals Inc (XENE) has a year-to-date price change of 10.06%. Over the past month, the stock has experienced a price change of 9.57%. Over the last three months, the change has been 44.92%. Over the past six months, the figure is 30.06%. Looking at a longer horizon, the five-year price change stands at 505.39%.

question_mark
Is Xenon Pharmaceuticals Inc (XENE) a profitable company?

Xenon Pharmaceuticals Inc (XENE) has a net income of -$175.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$203.69M. Furthermore, the EBITDA is -$200.48M.

question_mark
What is the market capitalization of Xenon Pharmaceuticals Inc (XENE)?

Xenon Pharmaceuticals Inc (XENE) has a market capitalization of $3.72B. The average daily trading volume is 405.63K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.